Inovio Pharmaceuticals (INO) Revenue (2010 - 2025)

Inovio Pharmaceuticals (INO) posted Revenue of $65343.0 for Q1 2025, down 44.15% sequentially from $116994.0 in Q4 2024.

Inovio Pharmaceuticals (INO) Revenue (2010 - 2025) Analysis & Trends

Inovio Pharmaceuticals has reported Revenue for 16 years, with the latest figure at $65343.0 in Q1 2025.

Quarterly Revenue changed N/A year-over-year to $65343.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $65343.0 (down 69.99% YoY) and the FY2025 annual result came in at $65343.0, down 69.99% from the prior year.
Revenue slipped to $65343.0 in Q1 2025 per INO's latest filing, from $116994.0 in the prior quarter.
Over five years, Revenue peaked at $9.2 million in Q3 2022 and troughed at $65343.0 in Q1 2025.
A 5-year average of $876809.0 and a median of $225971.0 in 2023 frame the typical range for Revenue.
The sharpest annual moves came in 2022 and 2023: Revenue soared 3038.22% in 2022, then slumped 95.76% in 2023.
Over 5 years, Revenue stood at $839115.0 in 2021, then sank by 85.14% to $124666.0 in 2022, then fell by 17.66% to $102651.0 in 2023, then gained by 13.97% to $116994.0 in 2024, then sank by 44.15% to $65343.0 in 2025.
According to Business Quant data, Revenue over the past three periods registered $65343.0, $116994.0, and $100762.0 for Q1 2025, Q4 2024, and Q2 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.52 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	1.29 Bn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	1.06 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	425.49 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	674.14 Mn
10	Inovio Pharmaceuticals	96.32 Mn	96.32 Mn	-	-

Download Data